The ectodomain of the short hydrophobic protein (SHe) of Respiratory Syncytial virus will be used as a recombinant virus-like particle in prophylactic vaccination studies against this virus. The protective efficacy of SHe-specific adaptive immunity will be characterized in a mouse model. Using passive transfer of antisera and immune cells the mechanism of protection of this novel vaccine will be determined.